The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain-Reference-Cited by-同舟云学术

The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain

Published:2021-03 Issue: Volume:185 Page:108445
ISSN:0028-3908
Container-title:Neuropharmacology
language:en
Short-container-title:Neuropharmacology

Author:

Atigari Diana Vivian,Paton Kelly Frances,Uprety Rajendra,Váradi András,Alder Amy Frances,Scouller Brittany,Miller John H.,Majumdar Susruta,Kivell Bronwyn Maree

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Pharmacology

Reference101 articles.

1. Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats;Abbott;Life Sci.,1988

2. Multifunctional opioid ligands;Anand,2018

3. MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats;Atigari;Neuropharmacology,2019

4. Evaluation of the Dmt− tic pharmacophore: conversion of a potent δ-opioid receptor antagonist into a potent δ agonist and ligands with mixed properties;Balboni;J. Med. Chem.,2002

5. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study;Berterame;Lancet,2016

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in attenuating opioid-induced respiratory depression: A narrative review;Medicine;2024-07-19

2. Systematic Structure–Activity Relationship Study of Nalfurafine Analogues toward Development of Potentially Nonaddictive Pain Management Treatments;Journal of Medicinal Chemistry;2024-05-30

3. KOR-Based Effect of Smo/Gli1 on the Development of Osteoarthritis Inflammation via Hedgehog (Hh) and Mechanism Study;J BIOL REG HOMEOS AG;2024

4. Recent Advances in Management of Neuropathic, Nociceptive, and Chronic Pain: A Narrative Review with Focus on Nanomedicine, Gene Therapy, Stem Cell Therapy, and Newer Therapeutic Options;Current Pain and Headache Reports;2024-02-22

5. Discovery of 7-Azanorbornane-Based Dual Agonists for the Delta and Kappa Opioid Receptors through an In Situ Screening Protocol;Molecules;2023-10-03